TSE:3498
TSE:3498Real Estate

Kasumigaseki Capital (TSE:3498) Q1 Revenue Growth Challenges Premium Valuation Narratives

Kasumigaseki CapitalLtd (TSE:3498) opened its Q1 2026 scorecard with revenue of ¥28.5b and basic EPS of ¥98.74, against a backdrop where the latest twelve month figures show revenue of ¥109.7b and basic EPS of ¥515.94. The company has seen quarterly revenue move from ¥16.9b in Q1 2025 to ¥28.5b in Q1 2026, while basic EPS over the same quarters went from ¥62.32 to ¥98.74. This sets up the current release against a period of solid top line and per share profit expansion. With a net profit...
TSE:3349
TSE:3349Consumer Retailing

COSMOS Pharmaceutical (TSE:3349) Margin Improvement Challenges Valuation Concerns In Q2 2026 Earnings

COSMOS Pharmaceutical (TSE:3349) has released its Q2 2026 scorecard, reporting revenue of ¥264.8b and basic EPS of ¥81.72. Trailing twelve month figures show ¥1.0t of revenue and EPS of ¥393.63. The company’s quarterly revenue has moved from ¥244.1b in Q2 2025 to ¥264.8b in Q2 2026, with basic EPS over that span ranging from ¥79.30 to ¥108.95 and trailing twelve month EPS rising from ¥344.38 to ¥393.63, setting this release against a backdrop of gradually firmer margins. See our full analysis...
TSE:8951
TSE:8951Office REITs

A Look At Nippon Building Fund (TSE:8951) Valuation After Guidance Upgrade And New Capital Raise

Nippon Building Fund (TSE:8951) has put capital plans in focus by pairing revised earnings and dividend guidance for 2026 with a follow-on equity offering and new long-term borrowing from MUFG Bank. See our latest analysis for Nippon Building Fund. The recent revisions to 2026 earnings and dividend guidance, together with fresh equity and long term borrowing, come after a steady 4.30% 90 day share price return and a 25.27% 1 year total shareholder return. This suggests momentum has been...